Evidence map›Paper›PMID 12212844›Full record

ArticleTransgenic research2002

The use of the uromodulin promoter to target production of recombinant proteins into urine of transgenic animals.

Halina M Zbikowska, Nadia Soukhareva, Reza Behnam, Rosemary Chang, Roman Drews, Henryk Lubon, David Hammond, Serguei Soukharev

Abstract read
PubMed Publisher
In one paragraph

Article in Transgenic research, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Uromodulin and progression of IgA nephropathy.Clinical kidney journal · 2024
    Article
  3. Review
  4. Article
  5. Transgenic mice and their impact on kidney research.Pflugers Archiv : European journal of physiology · 2009
    Review
  6. Cell engineering and molecular pharming for biopharmaceuticals.The open medicinal chemistry journal · 2008
    Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Halina M ZbikowskaPlasma Derivative Department, Holland Laboratory, American Red Cross, MD 20855, Rockville, USA.
Nadia Soukhareva
Reza Behnam
Rosemary Chang
Roman Drews
Henryk Lubon
David Hammond
Serguei Soukharev
American Red Cross · USUnited States Food and Drug Administration · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A uromodulin promoter has been isolated, sequenced, and used to generate two sets of transgenic mice for expression of the lacZ marker gene and for production of the human recombinant erythropoietin (rhEPO) in urine. We demonstrated that the 5.6-kb fragment of the uromodulin gene containing the 3.7-kb promoter area and, both the first exon and part of the second exon, were sufficient to provide kidney-specific expression of the lacZ gene. Histological analysis of the lacZ expression pattern revealed beta-galactosidase activity specifically in the thick limb of Henle's loop. However, due to random integration of the transgene, ectopic expression was detected in some transgenic lines. Analysis of the EPO-transgenic mice showed that rhEPO was secreted into the urine of founder mice (up to 6 ng/ml). We were able to breed and analyze only two sublines with a very low expression level of rhEPO (up to 260 pg/ml). All of our transgenic mice expressing rhEPO in urine developed disease symptoms similar to polycythemia in humans. These included a considerable increase in red blood cell counts, hemoglobin concentration, and hematocrit concomitant with severe thrombocytopenia, all of which were detected in the rhEPO-expressing mice. Although our model did not prove to be beneficial for commercial production of rhEPO, we concluded that the uromodulin promoter could be useful for expression of other important therapeutic proteins into the urine of transgenic animals.

Indexed as

Promoter Regions, GeneticAnimalsbeta-GalactosidaseDNA PrimersErythropoietinExonsFemaleGene Expression RegulationHumansKidneyMiceMice, TransgenicMucoproteinsOrgan SpecificityPolymerase Chain ReactionRecombinant Proteinsbeta-GalactosidaseDNA PrimersErythropoietinMucoproteinsRecombinant ProteinsUMOD protein, humanUmod protein, mouseUromodulin

Identifiers

PMID12212844
OpenAlexW296470603

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.